A
RCUS
Arcus Bioscience
30.34
+0.82+2.78%After Hours: 30.34 0.00 0.00%19:30 08/21 EDT
OPEN/PREV CLOSE29.89/29.52
TODAY RANGE29.74-30.56
VOL1.06M
MARKET CAP3.86B
52 WEEK RANGE9.81-31.74
AVG VOL (3M)1.32M
% TURNOVER0.83%
TURNOVER--
P/E (TTM)-7.7707
% RANGE2.78%
EPS(TTM)-3.9044
P/E(FORWARD)-8.4828
P/B8.30
BVPS3.654
DIVIDEND--
P/S15.39
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.73B
SHARES OUTSTANDING127.33M
NEXT EARNINGS10/26-10/30
FREE FLOAT90.13M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales
TipRanks·5d ago
Arcus Biosciences Bets Big on Casdatifan Pipeline
Simply Wall St·6d ago
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
TipRanks·08/13 16:30
Arcus Biosciences Locks In Key Casdatifan Data With Completed Phase 1 Study
Simply Wall St·08/13 15:30
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?
TipRanks·08/10 12:25
Morgan Stanley Keeps Their Hold Rating on Arcus Biosciences (RCUS)
TipRanks·08/07 10:32
Arcus Biosciences price target raised to $42 from $34 at Goldman Sachs
Simply Wall St·08/06 22:23
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses
Dow Jones·08/06 17:43
Arcus Biosciences Is Maintained at Equal-Weight by Wells Fargo
Dow Jones·08/06 15:55
Arcus Biosciences Is Maintained at Outperform by Wedbush
Dow Jones·08/06 15:55
Arcus Biosciences Price Target Raised to $43.00/Share From $41.00 by Wedbush
Benzinga·08/06 15:45
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43